Elekta (OTCMKTS:EKTAY – Get Free Report) and Insulet (NASDAQ:PODD – Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.
Analyst Ratings
This is a summary of current recommendations and price targets for Elekta and Insulet, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Elekta | 0 | 1 | 0 | 0 | 2.00 |
| Insulet | 2 | 11 | 13 | 0 | 2.42 |
Insulet has a consensus price target of $195.40, suggesting a potential upside of 43.54%. Given Insulet’s stronger consensus rating and higher probable upside, analysts clearly believe Insulet is more favorable than Elekta.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Elekta | -2.38% | 13.47% | 3.84% |
| Insulet | 12.29% | 29.29% | 13.31% |
Risk & Volatility
Elekta has a beta of 1.05, meaning that its stock price is 5% more volatile than the S&P 500. Comparatively, Insulet has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500.
Valuation and Earnings
This table compares Elekta and Insulet”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Elekta | $1.78 billion | 1.05 | -$55.38 million | ($0.12) | -42.38 |
| Insulet | $3.05 billion | 3.09 | $247.10 million | $5.35 | 25.44 |
Insulet has higher revenue and earnings than Elekta. Elekta is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.
Summary
Insulet beats Elekta on 12 of the 12 factors compared between the two stocks.
About Elekta
-logo-1200x675.png?v=20240604134456){kind=logo}
Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity for real-time MR visualization; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for image guided radiation therapy; treatment and workflow management solutions; radiation and medical oncology; and other patient services. It also provides Elekta Studio, an image guided brachytherapy solution; ImagingRing, a mobile CT scanner; Oncentra Brachy, a smart tool that facilitate repetitive tasks; Venezia applicator that enables the oncologist to treat locally advanced cervical cancer; Elekta Flexitron afterloader for enabling the precise execution of all steps in the workflow; Geneva, an applicator for cervical cancer treatment; veterinary radiation therapy products; and Elekta Kaiku for personalized cancer care. In addition, the company offers stereotactic radiosurgery, such as Leksell Gamma Knife Icon for personalized radiation treatment; Leksell Gamma Knife Perfexion, a tool for radiosurgeons; and Elekta Esprit. Further, it provides neurosurgery products comprising Leksell Vantage Stereotactic System for intracranial neurosurgery; and Leksell Stereotactic System for minimally invasive stereotactic neurosurgery. The company was incorporated in 1972 and is headquartered in Stockholm, Sweden.
About Insulet
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Receive News & Ratings for Elekta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elekta and related companies with MarketBeat.com's FREE daily email newsletter.
